# L_2015197EN.01001001.xml

| 25.7.2015 | EN | Official Journal of the European Union | L 197/10 |
| --- | --- | --- | --- |

25.7.2015

EN

Official Journal of the European Union

L 197/10

---

COMMISSION REGULATION (EU) 2015/1221

of 24 July 2015

amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

1

Whereas:

| (1) | Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC (2). |
| --- | --- |

(1)

Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC (2).

2

| (2) | Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation. |
| --- | --- |

(2)

Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation.

| (3) | With regard to the substance nitric acid ... % (EC number: 231-714-2), new scientific data has been made available for the hazard class ‘acute toxicity’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has issued an opinion on the new information, while all other classes covered by the earlier opinion should be included. |
| --- | --- |

(3)

With regard to the substance nitric acid ... % (EC number: 231-714-2), new scientific data has been made available for the hazard class ‘acute toxicity’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has issued an opinion on the new information, while all other classes covered by the earlier opinion should be included.

| (4) | With regard to the substance phenol, dodecyl-, branched (EC number: 310-154-3), the RAC is in the process of adopting a new opinion for the specific concentration limits to be applied to the hazard class ‘toxic for reproduction’. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until that opinion is finalised. |
| --- | --- |

(4)

With regard to the substance phenol, dodecyl-, branched (EC number: 310-154-3), the RAC is in the process of adopting a new opinion for the specific concentration limits to be applied to the hazard class ‘toxic for reproduction’. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until that opinion is finalised.

| (5) | Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3). |
| --- | --- |

(5)

Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3).

3

| (6) | In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance. |
| --- | --- |

(6)

In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

| (7) | The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006, |
| --- | --- |

(7)

The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.

Article 2

By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).

Article 3

1.   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

Official Journal of the European Union

2.   Article 1 shall apply in respect of substances and mixtures from 1 January 2017.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 24 July 2015.

For the Commission

The President

Jean-Claude JUNCKER

---

(1)  OJ L 353, 31.12.2008, p. 1.

1

(2)  Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).

2

(3)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

3

---

ANNEX

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

| (1) | Table 3.1 is amended as follows:






  (a) | the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:















  Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) |
| 007-004-00-1 | nitric acid ... % | 231-714-2 | 7697-37-2 | Ox. Liq. 2
  Skin Corr. 1A | H272
  H314 | GHS03
  GHS05
  Dgr | H272
  H314 | EUH071 | Skin Corr. 1A; H314: C ≥ 20 %
  Skin Corr. 1B; H314: 5 % ≤ C < 20 %
  Ox. Liq. 2; H272: C ≥ 99 %
  Ox. Liq. 3; H272: 99 % > C ≥ 65 % | B |
| 015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 | Water-react. 1
  Acute Tox. 2
  Acute Tox. 3
  Acute Tox. 1
  Eye Dam. 1
  Aquatic Acute 1 | H260
  H300
  H311
  H330
  H318
  H400 | GHS02
  GHS06
  GHS05
  GHS09
  Dgr | H260
  H300
  H311
  H330
  H318
  H400 | EUH029
  EUH032 | M = 100 | |
| 031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Repr. 1B
  Carc. 1B
  STOT RE 1 | H360F
  H350
  H372 (respiratory and haematopoietic systems) | GHS08
  Dgr | H360F
  H350
  H372 (respiratory and haematopoietic systems) | | | |
| 050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — | Repr. 1B
  Acute Tox. 3
  Acute Tox. 4*
  STOT RE 1
  Skin Irrit. 2
  Eye Irrit. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H360FD
  H301
  H312
  H372**
  H315
  H319
  H400
  H410 | GHS08
  GHS06
  GHS09
  Dgr | H360FD
  H301
  H312
  H372**
  H315
  H319
  H410 | | *
  STOT RE 1; H372: C ≥ 1 %
  STOT RE 2; H373: 0,25 % ≤ C < 1 %
  Skin Irrit. 2; H315:C ≥ 1 %
  Eye Irrit. 2; H319:C ≥ 1 %
  M = 10 | A
  1 |
| 603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 | Flam. Liq. 2
  Carc. 2
  Acute Tox. 4*
  Acute Tox. 4*
  Acute Tox. 4*
  STOT SE 3
  Skin Irrit. 2
  Eye Irrit. 2 | H225
  H351
  H302
  H312
  H332
  H335
  H315
  H319 | GHS02
  GHS08
  GHS07
  Dgr | H225
  H351
  H302
  H312
  H332
  H335
  H315
  H319 | | | |
| 603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. 2
  Acute Tox. 4
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d***
  H302
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H361d***
  H302
  H410 | | M = 1
  M = 10 | |
| 606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 | Repr. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d***
  H400
  H410 | GHS08
  GHS09
  Wng | H361d***
  H410 | | M = 10
  M = 100 | |
| 607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 | Skin Irrit. 2
  Eye Irrit. 2
  Aquatic Chronic 3 | H315
  H319
  H412 | GHS07
  Wng | H315
  H319
  H412 | | | |
| 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 | Carc. 2
  Acute Tox. 3
  Acute Tox. 4
  Eye Dam. 1
  Aquatic Chronic 1 | H351
  H301
  H332
  H318
  H410 | GHS08
  GHS06
  GHS05
  GHS09
  Dgr | H351
  H301
  H332
  H318
  H410 | | M = 10 | |
| 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 | Repr. 2
  STOT RE 2
  Skin Corr. 1C
  Skin Sens. 1A
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d
  H373 (liver)
  H314
  H317
  H400
  H410 | GHS08
  GHS05
  GHS07
  GHS09
  Dgr | H361d
  H373 (liver)
  H314
  H317
  H410 | EUH071 | M = 1
  M = 1 | |
| 613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 | Carc. 2
  Acute Tox. 4
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H302
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H351
  H302
  H317
  H410 | | M = 1
  M = 1 | |
| 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 | Acute Tox. 3
  Acute Tox. 3
  Aquatic Acute 1
  Aquatic Chronic 1 | H331
  H301
  H400
  H410 | GHS06
  GHS09
  Dgr | H331
  H301
  H410 | | M = 1 000
  M = 1 000 | |

(1)

Table 3.1 is amended as follows:

(a)

the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No

International Chemical Identification

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-factors

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

007-004-00-1

nitric acid ... %

231-714-2

7697-37-2

Ox. Liq. 2

Skin Corr. 1A

H272

H314

GHS03

GHS05

Dgr

H272

H314

EUH071

Skin Corr. 1A; H314: C ≥ 20 %

Skin Corr. 1B; H314: 5 % ≤ C < 20 %

Ox. Liq. 2; H272: C ≥ 99 %

Ox. Liq. 3; H272: 99 % > C ≥ 65 %

B

015-003-00-2

calcium phosphide; tricalcium diphosphide

215-142-0

1305-99-3

Water-react. 1

Acute Tox. 2

Acute Tox. 3

Acute Tox. 1

Eye Dam. 1

Aquatic Acute 1

H260

H300

H311

H330

H318

H400

GHS02

GHS06

GHS05

GHS09

Dgr

H260

H300

H311

H330

H318

H400

EUH029

EUH032

M = 100

031-001-00-4

gallium arsenide

215-114-8

1303-00-0

Repr. 1B

Carc. 1B

STOT RE 1

H360F

H350

H372 (respiratory and haematopoietic systems)

GHS08

Dgr

H360F

H350

H372 (respiratory and haematopoietic systems)

050-008-00-3

tributyltin compounds, with the exception of those specified elsewhere in this annex

—

—

Repr. 1B

Acute Tox. 3

Acute Tox. 4*

STOT RE 1

Skin Irrit. 2

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H360FD

H301

H312

H372**

H315

H319

H400

H410

GHS08

GHS06

GHS09

Dgr

H360FD

H301

H312

H372**

H315

H319

H410

*

STOT RE 1; H372: C ≥ 1 %

STOT RE 2; H373: 0,25 % ≤ C < 1 %

Skin Irrit. 2; H315:C ≥ 1 %

Eye Irrit. 2; H319:C ≥ 1 %

M = 10

A

1

603-102-00-9

1,2-epoxybutane

203-438-2

106-88-7

Flam. Liq. 2

Carc. 2

Acute Tox. 4*

Acute Tox. 4*

Acute Tox. 4*

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

H225

H351

H302

H312

H332

H335

H315

H319

GHS02

GHS08

GHS07

Dgr

H225

H351

H302

H312

H332

H335

H315

H319

603-197-00-7

tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol

403-640-2

107534-96-3

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H361d***

H302

H400

H410

GHS08

GHS07

GHS09

Wng

H361d***

H302

H410

M = 1

M = 10

606-054-00-7

isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone

—

141112-29-0

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d***

H400

H410

GHS08

GHS09

Wng

H361d***

H410

M = 10

M = 100

607-197-00-8

nonanoic acid

203-931-2

112-05-0

Skin Irrit. 2

Eye Irrit. 2

Aquatic Chronic 3

H315

H319

H412

GHS07

Wng

H315

H319

H412

613-042-00-5

imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole

252-615-0

35554-44-0

Carc. 2

Acute Tox. 3

Acute Tox. 4

Eye Dam. 1

Aquatic Chronic 1

H351

H301

H332

H318

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H351

H301

H332

H318

H410

M = 10

613-057-00-7

dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine

216-474-9

1593-77-7

Repr. 2

STOT RE 2

Skin Corr. 1C

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H361d

H373 (liver)

H314

H317

H400

H410

GHS08

GHS05

GHS07

GHS09

Dgr

H361d

H373 (liver)

H314

H317

H410

EUH071

M = 1

M = 1

613-133-00-X

etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole

219-991-8

2593-15-9

Carc. 2

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H317

H410

M = 1

M = 1

613-149-00-7

pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one

405-700-3

96489-71-3

Acute Tox. 3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H400

H410

GHS06

GHS09

Dgr

H331

H301

H410

M = 1 000

M = 1 000

| (b) | the following entries are inserted in accordance with the order of the entries set out in Table 3.1:















  Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) |
| 019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 | GSH07
  Wng | H319 | | | |
| 604-092-00-9 | phenol, dodecyl-, branched [1];
  phenol, 2-dodecyl-, branched;
  phenol, 3-dodecyl-, branched;
  phenol, 4-dodecyl-, branched;
  phenol, (tetrapropenyl) derivatives [2] | 310-154-3 [1] | 121158-58-5 [1]
  74499-35-7 [2] | Skin Corr. 1C
  Aquatic Acute 1
  Aquatic Chronic 1 | H314
  H400
  H410 | GHS05
  GHS09
  Dgr | H314
  H410 | | M = 10
  M = 10 | |
| 606-148-00-8 | carvone (ISO);
  2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]
  d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]
  l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] | 202-759-5 [1]
  218-827-2 [2]
  229-352-5 [3] | 99-49-0 [1]
  2244-16-8 [2]
  6485-40-1 [3] | Skin Sens. 1 | H317 | GHS07
  Wng | H317 | | | |
| 606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | — | 335104-84-2 | Repr. 2
  STOT RE 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H361d
  H373 (eyes, kidneys, liver)
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H361d
  H373 (eyes, kidneys, liver)
  H317
  H410 | | M = 100
  M = 10 | |
| 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 | STOT RE 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H373 (kidneys)
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H373 (kidneys)
  H317
  H410 | | M = 1
  M = 1 | |
| 607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 | Skin Corr. 1C
  Aquatic Chronic 3 | H314
  H412 | GHS05
  Dgr | H314
  H412 | | | |
| 607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 | Skin Irrit. 2
  Eye Irrit. 2
  Aquatic Chronic 3 | H315
  H319
  H412 | GHS07
  Wng | H315
  H319
  H412 | | | |
| 607-710-00-5 | 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD | GHS08
  Dgr | H360FD | | | |
| 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 | Repr. 2
  STOT SE 3
  Eye Irrit. 2
  Skin Sens. 1A
  Aquatic Acute 1
  Aquatic Chronic 1 | H361fd
  H335
  H319
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H361fd
  H335
  H319
  H317
  H410 | | M = 1
  M = 1 | |
| 607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 | Repr. 2
  STOT RE 2
  Skin Corr. 1C
  Skin Sens. 1A
  Aquatic Chronic 1 | H361d
  H373 (liver)
  H314
  H317
  H410 | GHS08
  GHS05
  GHS07
  GHS09
  Dgr | H361d
  H373 (liver)
  H314
  H317
  H410 | EUH071 | M = 1 | |
| 607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 | Acute Tox. 3
  Acute Tox. 2
  Skin Sens. 1B
  Aquatic Acute 1
  Aquatic Chronic 1 | H301
  H330
  H317
  H400
  H410 | GHS06 GHS09
  Dgr | H301
  H330
  H317
  H410 | | M = 100
  M = 1 000 | |
| 607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 | Carc. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H400
  H410 | GHS08
  GHS09
  Wng | H351
  H410 | | M = 100
  M = 10 | |
| 607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 | STOT RE 2
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H373
  H317
  H400
  H410 | GHS08
  GHS07
  GHS09
  Wng | H373
  H317
  H410 | | M = 1
  M = 1 | |
| 613-319-00-0 | imidazole | 206-019-2 | 288-32-4 | Repr. 1B
  Acute Tox. 4
  Skin Corr. 1C | H360D
  H302
  H314 | GHS08
  GHS07
  GHS05
  Dgr | H360D
  H302
  H314 | | | |
| 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 | Carc. 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H400
  H410 | GHS08
  GHS09
  Wng | H351
  H410 | | M = 10
  M = 10 | |
| 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | Aquatic Acute 1
  Aquatic Chronic 1 | H400
  H410 | GHS09
  Wng | H410 | | M = 1
  M = 1 | |
| 616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 | Carc. 2
  STOT RE 2
  Aquatic Acute 1
  Aquatic Chronic 1 | H351
  H373 (eyes, kidneys)
  H400
  H410 | GHS08
  GHS09
  Wng | H351
  H373 (eyes, kidneys)
  H410 | | M = 1 000
  M = 100 | |
| 616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 | Acute Tox. 4
  Skin Sens. 1
  Aquatic Acute 1
  Aquatic Chronic 1 | H302
  H317
  H400
  H410 | GHS07
  GHS09
  Wng | H302
  H317
  H410 | | M = 10
  M = 10 | |
| 616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Acute Tox. 4 | H302 | GHS07
  Wng | H302 | | | |
| 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 | Acute Tox. 4
  Aquatic Acute 1
  Aquatic Chronic 1 | H302
  H400
  H410 | GHS07
  GHS09
  Wng | H302
  H410 | | M = 1
  M = 1 | |

(b)

the following entries are inserted in accordance with the order of the entries set out in Table 3.1:

Index No

International Chemical Identification

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-factors

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

019-003-00-3

potassium (E,E)-hexa-2,4-dienoate

246-376-1

24634-61-5

Eye Irrit. 2

H319

GSH07

Wng

H319

604-092-00-9

phenol, dodecyl-, branched [1];

phenol, 2-dodecyl-, branched;

phenol, 3-dodecyl-, branched;

phenol, 4-dodecyl-, branched;

phenol, (tetrapropenyl) derivatives [2]

310-154-3 [1]

121158-58-5 [1]

74499-35-7 [2]

Skin Corr. 1C

Aquatic Acute 1

Aquatic Chronic 1

H314

H400

H410

GHS05

GHS09

Dgr

H314

H410

M = 10

M = 10

606-148-00-8

carvone (ISO);

2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]

d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]

l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]

202-759-5 [1]

218-827-2 [2]

229-352-5 [3]

99-49-0 [1]

2244-16-8 [2]

6485-40-1 [3]

Skin Sens. 1

H317

GHS07

Wng

H317

606-149-00-3

tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione

—

335104-84-2

Repr. 2

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H361d

H373 (eyes, kidneys, liver)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361d

H373 (eyes, kidneys, liver)

H317

H410

M = 100

M = 10

607-707-00-9

fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate

—

71283-80-2

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373 (kidneys)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373 (kidneys)

H317

H410

M = 1

M = 1

607-708-00-4

octanoic acid

204-677-5

124-07-2

Skin Corr. 1C

Aquatic Chronic 3

H314

H412

GHS05

Dgr

H314

H412

607-709-00-X

decanoic acid

206-376-4

334-48-5

Skin Irrit. 2

Eye Irrit. 2

Aquatic Chronic 3

H315

H319

H412

GHS07

Wng

H315

H319

H412

607-710-00-5

1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear

271-093-5

68515-50-4

Repr. 1B

H360FD

GHS08

Dgr

H360FD

607-711-00-0

spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate

—

203313-25-1

Repr. 2

STOT SE 3

Eye Irrit. 2

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H335

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361fd

H335

H319

H317

H410

M = 1

M = 1

607-712-00-6

dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate

250-778-2

31717-87-0

Repr. 2

STOT RE 2

Skin Corr. 1C

Skin Sens. 1A

Aquatic Chronic 1

H361d

H373 (liver)

H314

H317

H410

GHS08

GHS05

GHS07

GHS09

Dgr

H361d

H373 (liver)

H314

H317

H410

EUH071

M = 1

607-713-00-1

fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate

—

134098-61-6

Acute Tox. 3

Acute Tox. 2

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H301

H330

H317

H400

H410

GHS06 GHS09

Dgr

H301

H330

H317

H410

M = 100

M = 1 000

607-714-00-7

triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate

—

126535-15-7

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 100

M = 10

607-715-00-2

bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate

442-820-5

149877-41-8

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H373

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373

H317

H410

M = 1

M = 1

613-319-00-0

imidazole

206-019-2

288-32-4

Repr. 1B

Acute Tox. 4

Skin Corr. 1C

H360D

H302

H314

GHS08

GHS07

GHS05

Dgr

H360D

H302

H314

613-320-00-6

lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione

218-499-0

2164-08-1

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 10

M = 10

616-213-00-2

mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

—

374726-62-2

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

616-214-00-8

metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide

—

139528-85-1

Carc. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H373 (eyes, kidneys)

H400

H410

GHS08

GHS09

Wng

H351

H373 (eyes, kidneys)

H410

M = 1 000

M = 100

616-215-00-3

dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide

—

163515-14-8

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H317

H400

H410

GHS07

GHS09

Wng

H302

H317

H410

M = 10

M = 10

616-216-00-9

flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide

—

158062-67-0

Acute Tox. 4

H302

GHS07

Wng

H302

616-217-00-4

sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide

—

946578-00-3

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

M = 1

M = 1

| (2) | Table 3.2 is amended as follows:






  (a) | the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:












  Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 007-004-00-1 | nitric acid ... % | 231-714-2 | 7697-37-2 | O; R8
  C; R35 | O; C
  R: 8-35
  S: (1/2-)26-28- 36/37/39-45-63 | O; R8: C ≥ 65 %
  C; R35: C ≥ 20 %
  C; R34: 5 % ≤ C < 20 % | B |
| 015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 | F; R15/29
  T+; R26/28
  Xn; R21
  R32
  Xi; R38-41
  N; R50 | F; T+; N
  R: 15/29-21-26/28-32-38-41-50
  S:(1/2-)26-28-30-36/37/39-43-45-60-61 | N; R50: C ≥ 0,25 % | |
| 031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Repr. Cat. 2; R60
  Carc. Cat. 2; R45
  T; R48/23 | T
  R: 45-48/23-60
  S: 45-53 | | E |
| 050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — | Repr. Cat. 2; R60-61
  T; R25-48/23/25
  Xn; R21
  Xi; R36/38
  N; R50-53 | T; N
  R: 21-25-36/38-48/23/25-50/53-60-61
  S: 45-53-60-61 | T; R25: C ≥ 2,5 %
  Xn; R22: 0,25 % ≤ C < 2,5 %
  Xn: R21: C ≥ 1 %
  T; R48/23/25: C ≥ 1 %
  Xn; R48/20/22: 0,25 % ≤ C < 1 %
  Xi; R36/38: C ≥ 1 %
  N; R50-53: C ≥ 2,5 %
  N; R51-53: 0,25 % ≤ C < 2,5 %
  R52-53: 0,025 % ≤ C < 0,25 % | A
  1 |
| 603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 | F; R11
  Carc. Cat. 3; R40
  Xn; R20/21/22
  Xi; R36/37/38 | F; Xn
  R: 11-20/21/22-36/37/38-40-
  S: (2-)9-16-29-36/37-46 | | |
| 603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. Cat. 3; R63
  Xn; R22
  N; R50-53 | Xn; N
  R: 22-50/53-63
  S: (2-)22-36/37-60-61 | N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C <25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 | Repr. Cat. 3; R63
  N; R50-53 | Xn; N
  R: 50/53-63
  S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 %
  N; R51-53: 0,25 % ≤ C < 2,5 %
  R52-53: 0,025 % ≤ C < 0,25 % | |
| 607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 | Xi; R36/38
  N; R51-53 | Xi; N
  R: 36/38-51/53
  S: (2-)46-61 | | |
| 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 | Carc. Cat. 3; R40
  Xn; R20/22
  Xi; R41
  N; R51-53 | Xn; N
  R: 20/22-40-41-51/53
  S: (2-)26-36/37/39-46-61 | | |
| 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 | Repr. Cat. 3; R63
  C; R34
  R43
  N; R50-53 | C; N
  R: 34-43-50/53-63
  S: (1/2-)26-28-36/37/39-45-60-61 | C; R34: C ≥ 10 %
  Xi; R36/37/38: 5 % ≤ C < 10 %
  N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C < 25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 | Carc. Cat. 3; R40
  Xn; R22
  R43
  N; R50-53 | Xn; N
  R: 22-40-43-50/53
  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C < 25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 | T; R23/25
  N; R50-53 | T; N
  R: 23/25-50/53
  S: (1/2-)36/37-45-60-61 | N; R50-53: C ≥ 0,025 %
  N; R51-53: 0,0025 % ≤ C < 0,025 %
  R52-53: 0,00025 % ≤ C < 0,0025 % | |

(2)

Table 3.2 is amended as follows:

(a)

the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No

International Chemical Identification

EC No

CAS No

Classification

Labelling

Concentration Limits

Notes

007-004-00-1

nitric acid ... %

231-714-2

7697-37-2

O; R8

C; R35

O; C

R: 8-35

S: (1/2-)26-28- 36/37/39-45-63

O; R8: C ≥ 65 %

C; R35: C ≥ 20 %

C; R34: 5 % ≤ C < 20 %

B

015-003-00-2

calcium phosphide; tricalcium diphosphide

215-142-0

1305-99-3

F; R15/29

T+; R26/28

Xn; R21

R32

Xi; R38-41

N; R50

F; T+; N

R: 15/29-21-26/28-32-38-41-50

S:(1/2-)26-28-30-36/37/39-43-45-60-61

N; R50: C ≥ 0,25 %

031-001-00-4

gallium arsenide

215-114-8

1303-00-0

Repr. Cat. 2; R60

Carc. Cat. 2; R45

T; R48/23

T

R: 45-48/23-60

S: 45-53

E

050-008-00-3

tributyltin compounds, with the exception of those specified elsewhere in this annex

—

—

Repr. Cat. 2; R60-61

T; R25-48/23/25

Xn; R21

Xi; R36/38

N; R50-53

T; N

R: 21-25-36/38-48/23/25-50/53-60-61

S: 45-53-60-61

T; R25: C ≥ 2,5 %

Xn; R22: 0,25 % ≤ C < 2,5 %

Xn: R21: C ≥ 1 %

T; R48/23/25: C ≥ 1 %

Xn; R48/20/22: 0,25 % ≤ C < 1 %

Xi; R36/38: C ≥ 1 %

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

A

1

603-102-00-9

1,2-epoxybutane

203-438-2

106-88-7

F; R11

Carc. Cat. 3; R40

Xn; R20/21/22

Xi; R36/37/38

F; Xn

R: 11-20/21/22-36/37/38-40-

S: (2-)9-16-29-36/37-46

603-197-00-7

tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol

403-640-2

107534-96-3

Repr. Cat. 3; R63

Xn; R22

N; R50-53

Xn; N

R: 22-50/53-63

S: (2-)22-36/37-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C <25 %

R52-53: 0,25 % ≤ C < 2,5 %

606-054-00-7

isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone

—

141112-29-0

Repr. Cat. 3; R63

N; R50-53

Xn; N

R: 50/53-63

S: (2-)36/37-60-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

607-197-00-8

nonanoic acid

203-931-2

112-05-0

Xi; R36/38

N; R51-53

Xi; N

R: 36/38-51/53

S: (2-)46-61

613-042-00-5

imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole

252-615-0

35554-44-0

Carc. Cat. 3; R40

Xn; R20/22

Xi; R41

N; R51-53

Xn; N

R: 20/22-40-41-51/53

S: (2-)26-36/37/39-46-61

613-057-00-7

dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine

216-474-9

1593-77-7

Repr. Cat. 3; R63

C; R34

R43

N; R50-53

C; N

R: 34-43-50/53-63

S: (1/2-)26-28-36/37/39-45-60-61

C; R34: C ≥ 10 %

Xi; R36/37/38: 5 % ≤ C < 10 %

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

613-133-00-X

etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole

219-991-8

2593-15-9

Carc. Cat. 3; R40

Xn; R22

R43

N; R50-53

Xn; N

R: 22-40-43-50/53

S: (2-)36/37-46-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

613-149-00-7

pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one

405-700-3

96489-71-3

T; R23/25

N; R50-53

T; N

R: 23/25-50/53

S: (1/2-)36/37-45-60-61

N; R50-53: C ≥ 0,025 %

N; R51-53: 0,0025 % ≤ C < 0,025 %

R52-53: 0,00025 % ≤ C < 0,0025 %

| (b) | the following entries are inserted in accordance with the order of the entries set out in Table 3.2:












  Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Xi; R36 | Xi
  R: 36
  S: (2-)25-46 | | |
| 604-092-00-9 | phenol, dodecyl-, branched [1];
  phenol, 2-dodecyl-, branched;
  phenol, 3-dodecyl-, branched;
  phenol, 4-dodecyl-, branched;
  phenol, (tetrapropenyl) derivatives [2] | 310-154-3 [1]-[2] | 121158-58-5 [1]
  74499-35-7 [2] | C; R34
  N; R50-53 | C; N
  R: 34-50/53
  S: (1/2-)26-36/37/39-45-61 | N; R50-53: C ≥ 2,5 %
  N; R51-53: 0,25 % ≤ C < 2,5 %
  R52-53: 0,025 % ≤ C < 0,25 % | |
| 606-148-00-8 | carvone (ISO);
  2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]
  d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]
  l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] | 202-759-5 [1]
  218-827-2 [2]
  229-352-5 [3] | 99-49-0 [1]
  2244-16-8 [2]
  6485-40-1 [3] | R43 | Xi
  R: 43
  S: (2-)24-37 | | |
| 606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | | 335104-84-2 | Repr. Cat. 3; R63
  Xn; R48/22
  R43
  N; R50-53 | Xn; N
  R: 43-48/22-50/53-63
  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,25 %
  N; R51-53: 0,025 % ≤ C < 0,25 %
  R52-53: 0,0025 % ≤ C < 0,025 % | |
| 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 | Xn; R48/22
  R43
  N; R50-53 | Xn; N
  R: 43-48/22-50/53
  S: (2-)24-37-46-60-61 | N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C < 25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 | C; R34
  N; R51-53 | C; N
  R: 34-51/53
  S: (1/2-)26-36/37/39-45-61 | | |
| 607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 | Xi; R36/38
  N; R51-53 | Xi; N
  R: 36/38-51/53
  S: (2-)25-46-61 | | |
| 607-710-00-5 | 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. Cat. 2; R60-61 | T
  R: 60-61
  S: 53-45 | | |
| 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 | Repr. Cat. 3; R62-63
  Xi; R36/37
  R43
  N; R50-53 | Xn; N
  R: 36/37-43-50/53-62-63
  S: (2-)36/37-60-61 | Xi; R43: C ≥ 0,1 %
  N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C < 25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 | Repr. Cat. 3; R63
  C; R34
  R43
  N; R51-53 | C; N
  R: 34-43-51/53-63
  S: (1/2-)26-28-36/37/39-45-61 | C; R34: C ≥ 10 %
  Xi: R36/37/38: 5 % ≤ C < 10 % | |
| 607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 | T+; R26
  Xn; R22
  R43
  N; R50-53 | T+; N
  R: 22-26-43-50/53
  S: (1/2-)28-36/37-45-60-61-63 | N; R50-53: C ≥ 0,25 %
  N; R51-53: 0,025 % ≤ C < 0,25 %
  R52-53: 0,0025 % ≤ C < 0,025 % | |
| 607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 | Carc. Cat. 3; R40
  N; R50-53 | Xn; N
  R: 40-50/53
  S: (2-)36/37-60-61 | N; R50-53: C ≥ 0,25 %
  N; R51-53: 0,025 % ≤ C < 0,25 %
  R52-53: 0,0025 % ≤ C < 0,025 % | |
| 607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 | R43
  N; R50-53 | Xi; N
  R: 43-50/53
  S: (2-)24-37-60-61 | N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C < 25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 613-319-00-0 | imidazole | 206-019-2 | 288-32-4 | Repr. Cat 2; R61
  Xn; R22
  C; R34 | T; C
  R: 22-34-61
  S: 53-45 | | |
| 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 | Carc. Cat. 3; R40
  N; R50-53 | Xn; N
  R: 40-50/53
  S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 %
  N; R51-53: 0,25 % ≤ C < 2,5 %
  R52-53: 0,025 % ≤ C < 0,25 % | |
| 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | N; R50-53 | N
  R: 50/53
  S: 60-61 | N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C <25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |
| 616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 | Carc. Cat. 3; R40
  Xn; R48/22
  N; R50-53 | Xn; N
  R: 40-48/22-50/53
  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,025 %
  N; R51-53: 0,0025 % ≤ C < 0,025 %
  R52/53: 0,00025 % ≤ C < 0,0025 % | |
| 616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 | Xn; R22
  R43
  N; R50-53 | Xn; N
  R: 22-43-50/53
  S: (2-)24-37-60-61 | N; R50-53: C ≥ 2,5 %
  N; R51-53: 0,25 % ≤ C < 2,5 %
  R52-53: 0,025 % ≤ C < 0,25 % | |
| 616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Xn; R22 | Xn
  R: 22
  S: (2-)46 | | |
| 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 | Xn; R22
  N; R50-53 | Xn; N
  R: 22-50/53
  S: (2-)60-61 | N; R50-53: C ≥ 25 %
  N; R51-53: 2,5 % ≤ C < 25 %
  R52-53: 0,25 % ≤ C < 2,5 % | |

(b)

the following entries are inserted in accordance with the order of the entries set out in Table 3.2:

Index No

International Chemical Identification

EC No

CAS No

Classification

Labelling

Concentration Limits

Notes

019-003-00-3

potassium (E,E)-hexa-2,4-dienoate

246-376-1

24634-61-5

Xi; R36

Xi

R: 36

S: (2-)25-46

604-092-00-9

phenol, dodecyl-, branched [1];

phenol, 2-dodecyl-, branched;

phenol, 3-dodecyl-, branched;

phenol, 4-dodecyl-, branched;

phenol, (tetrapropenyl) derivatives [2]

310-154-3 [1]-[2]

121158-58-5 [1]

74499-35-7 [2]

C; R34

N; R50-53

C; N

R: 34-50/53

S: (1/2-)26-36/37/39-45-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

606-148-00-8

carvone (ISO);

2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]

d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]

l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]

202-759-5 [1]

218-827-2 [2]

229-352-5 [3]

99-49-0 [1]

2244-16-8 [2]

6485-40-1 [3]

R43

Xi

R: 43

S: (2-)24-37

606-149-00-3

tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione

335104-84-2

Repr. Cat. 3; R63

Xn; R48/22

R43

N; R50-53

Xn; N

R: 43-48/22-50/53-63

S: (2-)36/37-46-60-61

N; R50-53: C ≥ 0,25 %

N; R51-53: 0,025 % ≤ C < 0,25 %

R52-53: 0,0025 % ≤ C < 0,025 %

607-707-00-9

fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate

—

71283-80-2

Xn; R48/22

R43

N; R50-53

Xn; N

R: 43-48/22-50/53

S: (2-)24-37-46-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

607-708-00-4

octanoic acid

204-677-5

124-07-2

C; R34

N; R51-53

C; N

R: 34-51/53

S: (1/2-)26-36/37/39-45-61

607-709-00-X

decanoic acid

206-376-4

334-48-5

Xi; R36/38

N; R51-53

Xi; N

R: 36/38-51/53

S: (2-)25-46-61

607-710-00-5

1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear

271-093-5

68515-50-4

Repr. Cat. 2; R60-61

T

R: 60-61

S: 53-45

607-711-00-0

spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate

—

203313-25-1

Repr. Cat. 3; R62-63

Xi; R36/37

R43

N; R50-53

Xn; N

R: 36/37-43-50/53-62-63

S: (2-)36/37-60-61

Xi; R43: C ≥ 0,1 %

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

607-712-00-6

dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate

250-778-2

31717-87-0

Repr. Cat. 3; R63

C; R34

R43

N; R51-53

C; N

R: 34-43-51/53-63

S: (1/2-)26-28-36/37/39-45-61

C; R34: C ≥ 10 %

Xi: R36/37/38: 5 % ≤ C < 10 %

607-713-00-1

fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate

—

134098-61-6

T+; R26

Xn; R22

R43

N; R50-53

T+; N

R: 22-26-43-50/53

S: (1/2-)28-36/37-45-60-61-63

N; R50-53: C ≥ 0,25 %

N; R51-53: 0,025 % ≤ C < 0,25 %

R52-53: 0,0025 % ≤ C < 0,025 %

607-714-00-7

triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate

—

126535-15-7

Carc. Cat. 3; R40

N; R50-53

Xn; N

R: 40-50/53

S: (2-)36/37-60-61

N; R50-53: C ≥ 0,25 %

N; R51-53: 0,025 % ≤ C < 0,25 %

R52-53: 0,0025 % ≤ C < 0,025 %

607-715-00-2

bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate

442-820-5

149877-41-8

R43

N; R50-53

Xi; N

R: 43-50/53

S: (2-)24-37-60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

613-319-00-0

imidazole

206-019-2

288-32-4

Repr. Cat 2; R61

Xn; R22

C; R34

T; C

R: 22-34-61

S: 53-45

613-320-00-6

lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione

218-499-0

2164-08-1

Carc. Cat. 3; R40

N; R50-53

Xn; N

R: 40-50/53

S: (2-)36/37-60-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

616-213-00-2

mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

—

374726-62-2

N; R50-53

N

R: 50/53

S: 60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C <25 %

R52-53: 0,25 % ≤ C < 2,5 %

616-214-00-8

metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide

—

139528-85-1

Carc. Cat. 3; R40

Xn; R48/22

N; R50-53

Xn; N

R: 40-48/22-50/53

S: (2-)36/37-46-60-61

N; R50-53: C ≥ 0,025 %

N; R51-53: 0,0025 % ≤ C < 0,025 %

R52/53: 0,00025 % ≤ C < 0,0025 %

616-215-00-3

dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide

—

163515-14-8

Xn; R22

R43

N; R50-53

Xn; N

R: 22-43-50/53

S: (2-)24-37-60-61

N; R50-53: C ≥ 2,5 %

N; R51-53: 0,25 % ≤ C < 2,5 %

R52-53: 0,025 % ≤ C < 0,25 %

616-216-00-9

flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide

—

158062-67-0

Xn; R22

Xn

R: 22

S: (2-)46

616-217-00-4

sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide

—

946578-00-3

Xn; R22

N; R50-53

Xn; N

R: 22-50/53

S: (2-)60-61

N; R50-53: C ≥ 25 %

N; R51-53: 2,5 % ≤ C < 25 %

R52-53: 0,25 % ≤ C < 2,5 %

---